Dr. Fanale on Clinical Trials for T-Cell Lymphoma

Michelle A. Fanale
Published: Monday, Feb 27, 2017



Michelle A. Fanale, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses clinical trials for potential treatments for patients with T-cell lymphoma.

In the relapsed setting for patients with T-cell lymphoma, there are several doublet-based trials with romidepsin (Istodax), Fanale explains. There are plans to do randomized trials to compare 2 doublets versus romidepsin on its own.

Right now, a lot of the active clinical trials in the frontline setting look at a combination of chemotherapy plus one of the targeted agents, states Fanale. One of the eagerly awaited clinical trials is the ECHELON-2 trial, which focused on the combination of brentuximab vedotin (Adcetris) with CHP compared with CHOP, which is the standard of care. It has now completed enrollment but has not yet met its primary endpoint for progression-free survival.
 


Michelle A. Fanale, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses clinical trials for potential treatments for patients with T-cell lymphoma.

In the relapsed setting for patients with T-cell lymphoma, there are several doublet-based trials with romidepsin (Istodax), Fanale explains. There are plans to do randomized trials to compare 2 doublets versus romidepsin on its own.

Right now, a lot of the active clinical trials in the frontline setting look at a combination of chemotherapy plus one of the targeted agents, states Fanale. One of the eagerly awaited clinical trials is the ECHELON-2 trial, which focused on the combination of brentuximab vedotin (Adcetris) with CHP compared with CHOP, which is the standard of care. It has now completed enrollment but has not yet met its primary endpoint for progression-free survival.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Emerging Treatment Options for Patients With High-Risk AMLMay 31, 20181.0
Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Post-Transplant ObstaclesMay 31, 20181.0
Publication Bottom Border
Border Publication
x